CTRI/2017/03/008014CompletedPhase 3
A Multicentric, Double Blind, Randomized, Active Control, parallel, non-inferiority Clinical study to evaluate Efficacy, Safety of Vardenafil Tablets as compared with Sildenafil Tablets in treatment of erectile dysfunction.
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Ajanta Pharma Ltd
- Enrollment
- 219
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1.Subjects who have provided their written informed consent.
- •2.Subjects between the age of 21 and 65 (both inclusive)
- •3.Subjects with heterosexual relationship, with history of normal sexual function.
- •4.History of Erectile Dysfunction for at least 4 weeks.
- •5.Subjects meeting with diagnostic criteria for erectile dysfunction as per the simplified international index of erectile function (IIEF-5) score lesser than 22 and more than 5.
- •6.Penile Doppler standard systolic and diastolic velocity range for inclusions ( <25 cm/sec as definite arterial dysfunction and 25-30 cm/sec as borderline case.)
- •7.Subjects willing to participate in the study and follow visit schedule, including response to the questions related with the sexual function information for both himself and his spouseâ??s and information on sexual intercourse
Exclusion Criteria
- •1.Subjects engaged in polygamy, anal penetration, and homosexual relationships.
- •2.Subjects and their female partner of the child bearing age who are not able to follow adequate contraceptive measures during the course of the study.
- •3.Subjects with history of or underlying cardiovascular condition, myocardial infarction, cardiac arrhythmia, heart failure, unstable angina, resting or postural hypotension or hypertension (Uncontrolled Hypertension 180/100 mmHg).
- •4.Primary hypoactive sexual desire, Spinal cord injury, Pelvic surgery Presence of penile anatomical abnormalities
- •5.Subjects for whom sexual activity is inadvisable because of their underling disease status.
- •6.Subjects having bleeding disorder.
- •7.Subjects with hereditary degenerative retinal disorders.
- •8.Subjects with history of loss of vision because of non-arteritic anterior ischemic optic neuropathy.
- •9.Subjects with abnormal laboratory values for Serum total testosterone level, Serum creatinine and Serum AST and/or ALT.
- •10.Subjects with history of cancer.
- •11.Subjects with history of chronic headache or migraine.
- •12.Subjects with History of Space occupying lesion in cranium.
- •13.Subjects with general neurasthenia, myasthenia, depression that required medical treatment, syncope or fainting episodes within 6 months of baseline visit or seizures, demyelinating neurological disorders.
- •14.Subjects with history of ototoxicity from any drug in the past or impaired hearing unless corrected surgically at least 6 months before the baseline visit.
- •15.Subjects with Type 1 and uncontrolled Type 2 Diabetes Mellitus (i.e. defined as FPG levels of >=125 mg/dL and Glycosylated HbA1C Level >7%).
- •16.Subjects with history of sexually transmitted diseases, HIV infection or AIDS, Hepatitis B & C, fungus infection requiring systemic antifungal.
- •17.Subjects with a positive VDRL test
- •18.Subjects who are taking nitrates or nitric oxide donors, androgens, anti-androgens, alpha- blockers, medication known to prolong QT interval, Human immunodeficiency virus (HIV) protease inhibitors, Itraconazole or ketoconazole, clarithromycin and erythromycin.
- •19.Subjects with history of alcohol or drug abuse.
Investigators
Similar Trials
Completed
Phase 3
A Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Nepafenac Ophthalmic Suspension 0.3% w/v compared to Bromfenac Ophthalmic Solution 0.09% w/v in the treatment of Pain and Inflammation post Cataract Surgery.CTRI/2017/04/008299Ajanta Pharma Ltd240
Completed
Phase 3
A Clinical study to evaluate Efficacy, Safety and Tolerability of 2% Rebamipide ophthalmic suspension Vs 0.1 % Sodium Hyaluronate Ophthalmic solution for treatment of patients with Dry EyeCTRI/2015/05/005783Ajanta Pharma Ltd200
Completed
Phase 3
Fixed dose combination of Azilsartan medoxomil and Chlorthalidone for tratment of hypertensioCTRI/2017/12/010961SYNOKEM Pharmaceuticals Limited306
Recruiting
Phase 3
A multiple centre Phase III study of Azelnidipine in Newly Diagnosed Patients with Mild to Moderate Hypertension.CTRI/2015/08/006136Precise Chemipharma Pvt Ltd600
Completed
Phase 3
Effects of Levomilnacipran ER capsule for treatment of patients with major depressive disorder comparing to Venlafaxine hydrochloride XR capsuleCTRI/2017/10/010060MSN Laboratories Private Limited240